These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 25002131

  • 1. Interplay of parathyroid hormone and aldosterone antagonist in prevention of heart failure hospitalizations in chronic kidney disease.
    Hassan M, Qureshi W, Sroujieh LS, Albashaireh D, BouMalham S, Liroff M, Amjad W, Khalid F, Hadid H, Alirhayim Z.
    J Renin Angiotensin Aldosterone Syst; 2014 Sep; 15(3):278-85. PubMed ID: 25002131
    [Abstract] [Full Text] [Related]

  • 2. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
    Tomaschitz A, Ritz E, Pieske B, Rus-Machan J, Kienreich K, Verheyen N, Gaksch M, Grübler M, Fahrleitner-Pammer A, Mrak P, Toplak H, Kraigher-Krainer E, März W, Pilz S.
    Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
    [Abstract] [Full Text] [Related]

  • 3. Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure).
    Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B, EMPHASIS-HF Investigators.
    J Am Coll Cardiol; 2013 Oct 22; 62(17):1585-93. PubMed ID: 23810881
    [Abstract] [Full Text] [Related]

  • 4. Are beta-blockers needed in patients receiving spironolactone for severe chronic heart failure? An analysis of the COPERNICUS study.
    Krum H, Mohacsi P, Katus HA, Tendera M, Rouleau JL, Fowler MB, Coats AJ, Roecker EB, Packer M, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group.
    Am Heart J; 2006 Jan 22; 151(1):55-61. PubMed ID: 16368292
    [Abstract] [Full Text] [Related]

  • 5. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease.
    Seiler-Mussler S, Limbach AS, Emrich IE, Pickering JW, Roth HJ, Fliser D, Heine GH.
    Clin J Am Soc Nephrol; 2018 Apr 06; 13(4):569-576. PubMed ID: 29507005
    [Abstract] [Full Text] [Related]

  • 6. Update on aldosterone antagonists use in heart failure with reduced left ventricular ejection fraction. Heart Failure Society of America Guidelines Committee.
    Butler J, Ezekowitz JA, Collins SP, Givertz MM, Teerlink JR, Walsh MN, Albert NM, Westlake Canary CA, Carson PE, Colvin-Adams M, Fang JC, Hernandez AF, Hershberger RE, Katz SD, Rogers JG, Spertus JA, Stevenson WG, Sweitzer NK, Tang WH, Stough WG, Starling RC.
    J Card Fail; 2012 Apr 06; 18(4):265-81. PubMed ID: 22464767
    [Abstract] [Full Text] [Related]

  • 7. Eplerenone and new-onset diabetes in patients with mild heart failure: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF).
    Preiss D, van Veldhuisen DJ, Sattar N, Krum H, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B, Zannad F, McMurray JJ.
    Eur J Heart Fail; 2012 Aug 06; 14(8):909-15. PubMed ID: 22611047
    [Abstract] [Full Text] [Related]

  • 8. Aldosterone antagonist therapy and its relationship with inflammation, fibrosis, thrombosis, mineral-bone disorder and cardiovascular complications in peritoneal dialysis (PD) patients.
    Donderski R, Stróżecki P, Sulikowska B, Grajewska M, Miśkowiec I, Stefańska A, Siódmiak J, Odrowąż-Sypniewska G, Manitius J.
    Int Urol Nephrol; 2017 Oct 06; 49(10):1867-1873. PubMed ID: 28710615
    [Abstract] [Full Text] [Related]

  • 9. Clinical benefit of spironolactone in patients with acute decompensated heart failure and severe renal dysfunction: Data from the Korean Heart Failure Registry.
    Oh J, Kang SM, Song MK, Hong N, Youn JC, Han S, Jeon ES, Cho MC, Kim JJ, Yoo BS, Chae SC, Oh BH, Choi DJ, Lee MM, Ryu KH.
    Am Heart J; 2015 May 06; 169(5):713-720.e3. PubMed ID: 25965719
    [Abstract] [Full Text] [Related]

  • 10. Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues.
    Kalidindi SR, Tang WH, Francis GS.
    Nat Clin Pract Cardiovasc Med; 2007 Jul 06; 4(7):368-78. PubMed ID: 17589427
    [Abstract] [Full Text] [Related]

  • 11. Blocking aldosterone in heart failure.
    Shafiq MM, Miller AB.
    Ther Adv Cardiovasc Dis; 2009 Oct 06; 3(5):379-85. PubMed ID: 19661156
    [Abstract] [Full Text] [Related]

  • 12. [Are aldosterone antagonists effective in patients with mild to moderate heart failure?].
    Rada G, Peña J.
    Medwave; 2014 Jul 15; 14(6):e5999. PubMed ID: 25353251
    [Abstract] [Full Text] [Related]

  • 13. Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease.
    Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F.
    Eur J Heart Fail; 2012 Jun 15; 14(6):668-75. PubMed ID: 22562554
    [Abstract] [Full Text] [Related]

  • 14. Prognostic value of aldosterone and cortisol in patients hospitalized for acutely decompensated chronic heart failure with and without mineralocorticoid receptor antagonism.
    Güder G, Hammer F, Deutschbein T, Brenner S, Berliner D, Deubner N, Bidlingmaier M, Ertl G, Allolio B, Angermann CE, Fassnacht M, Störk S.
    J Card Fail; 2015 Mar 15; 21(3):208-16. PubMed ID: 25573831
    [Abstract] [Full Text] [Related]

  • 15. Adherence to aldosterone-blocking agents in patients with heart failure.
    Margolis J, Gerber RA, Roberts C, Gheorghiade M.
    Am J Ther; 2010 Mar 15; 17(5):446-54. PubMed ID: 20844344
    [Abstract] [Full Text] [Related]

  • 16. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD, Nawarskas JJ, Anderson JR.
    Heart Dis; 2003 Mar 15; 5(5):354-63. PubMed ID: 14503934
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Effects of mineralocorticoid receptor antagonist spironolactone on cardiac sympathetic nerve activity and prognosis in patients with chronic heart failure.
    Kasama S, Toyama T, Sumino H, Kumakura H, Takayama Y, Minami K, Ichikawa S, Matsumoto N, Sato Y, Kurabayashi M.
    Int J Cardiol; 2013 Jul 15; 167(1):244-9. PubMed ID: 22245478
    [Abstract] [Full Text] [Related]

  • 19. Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure.
    Güder G, Bauersachs J, Frantz S, Weismann D, Allolio B, Ertl G, Angermann CE, Störk S.
    Circulation; 2007 Apr 03; 115(13):1754-61. PubMed ID: 17372171
    [Abstract] [Full Text] [Related]

  • 20. The role of aldosterone in heart failure and the clinical benefits of aldosterone blockade.
    Dawson A, Davies JI, Struthers AD.
    Expert Rev Cardiovasc Ther; 2004 Jan 03; 2(1):29-36. PubMed ID: 15038411
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.